BioSpace News Archive

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EST.

Flow Neuroscience, the creators of the Flow tDCS headset that provides at-home non-invasive brain stimulation to treat depression, today announced the results of its FDA pivotal clinical trial.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology.

Biovica announces that the company has signed a commercial agreement with Occum Health for DiviTum® TKa in the US, making the blood test available to the more than 500 self-insured clients and key strategic partners.

Biosion USA, Inc., a global clinical-stage R&D biotechnology company, announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis .

Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, released its Appendix 4C – Quarterly Cashflow Report.

Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., and Medpod Inc. announced the launch of Medpac – a lightweight, portable telediagnostic solution that allows health care providers to offer comprehensive professional care regardless of location, helping to bridge the gap between remote telemedicine consultations and in-person office visits.

Castellum, Inc. is pleased to announce that its revenue for the second quarter of 2023 was a record.

Harrow, a leading U.S. eyecare pharmaceutical company, announced the completion of the transfer to Harrow of the New Drug Application for VIGAMOX® 0.5%, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

Enanta Pharmaceuticals, Inc . today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023.